A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)
- 13 April 2026
- journal article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 27 (5) , 5-10
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development (JP25ck0106028)
This publication has 16 references indexed in Scilit:
- Improved Event-Free Survival After Complete or Major Pathologic Response in Patients With Resectable NSCLC Treated With Neoadjuvant Chemoimmunotherapy Regardless of Adjuvant Treatment: A Systematic Review and Individual Patient Data Meta-AnalysisJournal of Thoracic Oncology, 2024
- Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2024
- Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung CancerJournal of Thoracic Oncology, 2024
- Perioperative Nivolumab in Resectable Lung CancerNew England Journal of Medicine, 2024
- Perioperative Durvalumab for Resectable Non–Small-Cell Lung CancerNew England Journal of Medicine, 2023
- The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: An Overview of the Central Database Informing Revision of the Forthcoming (Ninth) Edition of the TNM Classification of Malignant TumorsJournal of Thoracic Oncology, 2023
- Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialThe Lancet Oncology, 2022
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialThe Lancet, 2021
- Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteriaSurgery Today, 2015
- Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient dataThe Lancet, 2010